These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease. Krafft GA; Jerecic J; Siemers E; Cline EN Front Neurosci; 2022; 16():848215. PubMed ID: 35557606 [TBL] [Abstract][Full Text] [Related]
8. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294 [TBL] [Abstract][Full Text] [Related]
9. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170 [TBL] [Abstract][Full Text] [Related]
11. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Sampson EL; Jenagaratnam L; McShane R Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040 [TBL] [Abstract][Full Text] [Related]
13. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035 [TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical Tariot PN; Lopera F; Langbaum JB; Thomas RG; Hendrix S; Schneider LS; Rios-Romenets S; Giraldo M; Acosta N; Tobon C; Ramos C; Espinosa A; Cho W; Ward M; Clayton D; Friesenhahn M; Mackey H; Honigberg L; Sanabria Bohorquez S; Chen K; Walsh T; Langlois C; Reiman EM; Alzheimers Dement (N Y); 2018; 4():150-160. PubMed ID: 29955659 [TBL] [Abstract][Full Text] [Related]
15. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770 [TBL] [Abstract][Full Text] [Related]
16. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576 [TBL] [Abstract][Full Text] [Related]
17. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H; Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152 [TBL] [Abstract][Full Text] [Related]
18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833 [TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321 [TBL] [Abstract][Full Text] [Related]
20. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. Papp KV; Rentz DM; Maruff P; Sun CK; Raman R; Donohue MC; Schembri A; Stark C; Yassa MA; Wessels AM; Yaari R; Holdridge KC; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2021; 8(1):59-67. PubMed ID: 33336226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]